JP Morgan Chase’s DA32 Life Science Tech Acquisition Corp DALS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-250,000
Closed -$2.53M – 7480
2023
Q1
$2.53M Buy
250,000
+175,000
+233% +$1.76M ﹤0.01% 3368
2022
Q4
$750K Sell
75,000
-24,500
-25% -$241K ﹤0.01% 4248
2022
Q3
$964K Sell
99,500
-50,500
-34% -$491K ﹤0.01% 4035
2022
Q2
$1.45M Hold
150,000
– – ﹤0.01% 3813
2022
Q1
$1.46M Sell
150,000
-139,000
-48% -$1.34M ﹤0.01% 4008
2021
Q4
$2.84M Sell
289,000
-10,349
-3% -$101K ﹤0.01% 3551
2021
Q3
$2.94M Buy
+299,349
New +$2.96M ﹤0.01% 3470

Other funds holding DALS

JP Morgan Chase's DALS Position: Q2 2023 in Review

JP Morgan Chase sold out of DA32 Life Science Tech Acquisition Corp (DALS) in Q2 2023, closing a stake of 250,000 shares — an estimated $2.53M sold.

JP Morgan Chase first reported a position in DALS in Q3 2021 and held it in 7 quarters. The position peaked at $2.94M in Q3 2021. 50 funds tracked by Wall St. Rank hold DALS as of Q2 2023.

  • JP Morgan Chase reported no remaining DA32 Life Science Tech Acquisition Corp position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 250,000 DA32 Life Science Tech Acquisition Corp shares in Q2 2023, an estimated $2.53M.
  • JP Morgan Chase first reported a position in DA32 Life Science Tech Acquisition Corp in Q3 2021 and held it in 7 quarters.
  • JP Morgan Chase's DA32 Life Science Tech Acquisition Corp position peaked at $2.94M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.